

# Comparison of Atorvastatin and Simvastatin Modulation on Adiponectin and Insulin Resistance In Non-Diabetic Dyslipidemic Patients

Megawaty Megawaty<sup>1</sup>, Muzayyidah Muzayyidah<sup>1</sup>, Yulia Yusrini Djibir<sup>2\*</sup>, Idar Mappangara<sup>3</sup>, Bogie Palinggi<sup>4</sup>

<sup>1</sup>Graduate Program, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia

<sup>2</sup>Laboratory of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia

<sup>3</sup>Department of Cardiovascular Medicine, Medical Faculty, Hasanuddin University, Makassar, Indonesia

<sup>4</sup>Department of Cardiology and Vascular Medicine, Labuang Baji General Hospital, Makassar, Indonesia

## ABSTRACT

Statins are the first-line treatment of dyslipidemia but their use is associated with an increased risk of impaired glycemic control. In this study, the effects of atorvastatin and simvastatin on adiponectin levels and insulin resistance index were compared in non-diabetic dyslipidemic patients. Thirty-nine dyslipidemic non-diabetic outpatients were included in this study. The patients were prescribed with either simvastatin 20 mg or atorvastatin 20 mg. Blood sampling was carried out before and two months after statin treatments to measure the adiponectin, insulin, and fasting blood glucose (FBG) levels. The insulin resistance index was calculated based on the Homeostatic Model Assessment-Insulin Resistance (HOMA-IR). Most patients had low baseline adiponectin levels (<3 µg/dl) and were not significantly changed after two months of atorvastatin or simvastatin treatment. Fasting insulin levels significantly increased in the simvastatin group ( $p=0.033$ ), but not in the atorvastatin group. The HOMA-IR index was also increased in the simvastatin group from  $1.89 \pm 4.51$  before to  $2.72 \pm 5.86$  after treatment but did not reach statistical significance. Further analysis found a positive correlation between fasting insulin level and HOMA-IR value and the simvastatin group's adiponectin level ( $p=0.001$ ). There is an indication that simvastatin, but not atorvastatin, stimulates an increase in fasting insulin levels after two months of treatments. The increase in the insulin resistance index correlates to the plasma level of adiponectin. Further study with a longer duration of observation is required to address this potential side effect.

**Keywords:** Simvastatin; atorvastatin; glycemic control; adiponectin; insulin resistance index

## Introduction

Dyslipidemia is a metabolism disorder characterized by increased total cholesterol and low-density lipoprotein cholesterol (LDL-C) and decreased high-density lipoprotein cholesterol (HDL-C) levels (1). Dyslipidemia can be triggered by high-fat diet leading to metabolic disorders, both in humans (2) and animal models (3). Statins have been established as the first-line therapy for dyslipidemia, since they can reduce LDL-C levels and decrease the risks of coronary heart diseases, stroke, and death (4). Statins act by inhibiting the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase which is responsible for cholesterol biosynthesis (5). The inhibition of

HMG-CoA reductase activity may also generate a pleiotropic effect (6), adding further benefits for statin use in hypercholesterolemic patients (7).

Since 2012, the Food and Drug Administration (FDA) has disclosed the risk of hyperglycemia and increased glycosylated hemoglobin (HbA<sub>1c</sub>) by statins. Based on observational studies and meta-analysis, around 10-12% of the new onset of diabetes mellitus (NODM) has been implicated with the use of statins (8). This leads to controversy on statin use in patients with diabetes mellitus (9). Several hypotheses try to explain the mechanism of statin-induced diabetogenesis, including the impairment of pancreatic beta-cell function and reduction of insulin sensitivity by statins (8). However, whether the

\*Corresponding Author: Yulia Yusrini Djibir, Laboratory of Clinical Pharmacy, Faculty of Pharmacy, Hasanuddin University, Indonesia 90245

E-mail: yulia.yusrini@unhas.ac.id

ORCID ID: Megawaty Megawaty: 0000-0003-0389-4858, Muzayyidah Muzayyidah: 0000-0003-1385-8201, Yulia Yusrini Djibir: 0000-0002-5891-7247, Idar Mappangara: 0000-0002-1161-6754, Bogie Palinggi: 0000-0002-4324-9151

Received: 23.01.2022, Accepted: 29.12.2022

diabetogenic risks of statins are similar to all types of statins remains disputed (8).

Insulin is a polypeptide that is synthesized and released from the  $\beta$ -cell pancreas, thus, the level of insulin is disrupted during pancreatic damage (10). However, the diabetogenic effect of statins is not likely to be related to pancreatic injury. Instead, plasma adiponectin level, a specific protein in adipose tissue, has been claimed as a good indicator of insulin sensitivity as reduced adiponectin levels may lead to impaired glucose metabolism (11). Clinical studies have shown a decrease in plasma adiponectin is mostly found in obese individuals, type-2 diabetes mellitus, metabolic syndrome, and coronary artery disease patients (12). Adiponectin has been demonstrated to stimulate insulin gene expression in pancreatic  $\beta$ -cells (13). In addition, the anti-apoptotic effect of adiponectin may protect against pancreatic  $\beta$ -cell apoptosis, thereby, increasing insulin production (14).

Several reports have shown that statin-induced insulin resistance is associated with reduced plasma adiponectin levels (15, 16). However, the effects of statin therapy on adiponectin levels remain contradictory as some studies also demonstrate no change or increased adiponectin levels in patients receiving different types of statins (17-19). Therefore, this study aimed to compare the effect of atorvastatin and simvastatin use on adiponectin levels and insulin resistance index in patients diagnosed with nondiabetic dyslipidemia.

## Material and Methods

**Subjects:** The subjects were recruited from consecutive outpatients (n=39) attending Universitas Hasanuddin teaching hospitals and Labuang Baji regional hospitals in Makassar, Indonesia. The diagnosis of dyslipidemia is defined if the patients meet one of the categories of dyslipidemia according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), i.e. increased plasma levels of total cholesterol  $\geq 200$  mg/dL, low-density lipoprotein (LDL) cholesterol  $\geq 100$  mg/dL, triglycerides  $\geq 150$  mg/dL, and reduced high-density lipoprotein (HDL) cholesterol  $< 40$  mg/dL. Patients with type-2 diabetes mellitus (DM) were excluded from this study. All subjects were adults  $> 18$  years old and prescribed with either simvastatin 40 mg/day or atorvastatin 20 mg/day. Subjects who met the inclusion criteria have been explained about the

study and have signed the informed consent before participating in this study.

**Data Collection:** All procedures carried out in this study complied with the institutional policy and protocols for human subject research studies and have been granted an ethical clearance (No. 832/UN4.6.4.5.31/PP36/2019). Questionnaires, medical records, and direct interviews were used to obtain patients' details, history of treatments and diseases, diet, and physical activities. Physical activities were categorized (as low, moderate, or high) based on the international physical activities questionnaire (IPAQ) (20). The measurement of body mass index (BMI) is performed by anthropometric techniques.

Patients were divided into two treatment groups, either simvastatin or atorvastatin group. Blood samples were withdrawn prior to initiation and following 2 months post statin therapy. The lipid profiles and fasting blood glucose (FBG) levels were measured using a hematology analyzer (ABX Pentra 60, HORIBA). Meanwhile, the plasma levels of adiponectin and insulin were measured using an enzyme-like immunosorbent assay (ELISA) reader (Thermo Fisher Scientific) with human adiponectin or insulin ELISA kit (Bioassay Technology Laboratory). Based on the FBG and fasting insulin levels, the insulin resistance index was calculated using the Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) calculations (21).

$$\text{HOMA-IR} = \frac{\text{Fasting insulin } (\mu\text{U/mL}) \times \text{FBG } (\text{mmol/L})}{22.5}$$

**Statistical Analysis:** Data are presented as mean  $\pm$  standard deviation. The distribution of data was analyzed using a Kolmogorov-Smirnov analysis. Since data were not normally distributed, the significant difference between the two groups was compared using a Mann-Whitney U-test, while the differences between pre- and post-treatments were analyzed with a Wilcoxon test. The correlation analysis was performed using Spearman's rho correlation analysis. A significant difference or correlation is defined if the p-value is less than 0.05.

## Results

The demographic data collected include sex, age, body mass index (BMI), physical activities, and medication history. The details of patients' demography are presented in Table 1.

**Table 1:** The Demographic Data of Non-Diabetic Dyslipidemic Patients Receiving Either 20 mg Atorvastatin or 20 mg Simvastatin

Patients' demography	Atorvastatin (N, %)	Simvastatin (N, %)	P value
Sex			
Male	9 (45)	11 (58)	0.427
Female	11 (55)	8 (42)	
Age (years)			
35-45	1 (5)	0 (0)	
46-55	7 (35)	4 (21)	0.028
56-65	8 (40)	4 (21)	
>66	4 (20)	11 (58)	
BMI (kg/m <sup>2</sup> )			
>25 (obese)	10 (50)	9 (47)	
23-24.9 (overweight)	6 (30)	6 (32)	0.927
18.5-22.9 (normal)	3 (15)	4 (21)	
<18.5 (underweight)	1 (5)	0 (0)	
Physical activity <sup>a</sup>			
Low	8 (40)	8 (42)	
Moderate	12 (60)	11 (58)	0.895
High	0 (0)	0 (0)	
Medication history <sup>b</sup>			
ACEI	3 (15)	6 (32)	
ARB	8 (40)	9 (47)	0.238
BB	12 (60)	14 (74)	
CCB	6 (30)	7 (37)	

<sup>a</sup>Based on the IPAQ 2005 questionnaires. BMI: body mass index; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BB: beta-blocker; CCB: calcium channel inhibitor. <sup>b</sup>Most patients received a combination of antihypertensive agents

23

**Table 2:** The Mean Adiponectin, Fasting Blood Glucose, Fasting Insulin Levels, and HOMA-IR Value in The Atorvastatin and Simvastatin Groups

Treatment	Variables	Baseline	Post-treatment	p-value
Atorvastatin	Adiponectin (mg/L)	8.44 ± 17.33	5.72 ± 9.18	0.841
	Fasting insulin (μU/mL)	6.93 ± 14.02	7.07 ± 15.02	0.794
	FBG (mg/dl)	105.3 ± 13.44	109.7 ± 31.97	0.968
	HOMA-IR	1.82 ± 3.77	1.89 ± 4.11	0.940
Simvastatin	Adiponectin (mg/L)	7.66 ± 14.06	11.05 ± 23.27	0.260
	Fasting insulin (μU/mL)	7.28 ± 16.68	11.83 ± 26.74	0.033*
	FBG (mg/dl)	101.0 ± 13.18	100.2 ± 10.88	0.798
	HOMA-IR	1.89 ± 4.51	2.72 ± 5.86	0.107

Data expressed as mean ± SD; FBG: Fasting Blood Glucose; HOMA-IR: Homeostatic Model Assessment-Insulin Resistance; p-values based on Wilcoxon test

This study involved 39 non-diabetic dyslipidemic patients, consisting of 20 male (51%) and 19 female patients (49%). The majority of these dyslipidemic patients aged between 46 and 65 years old (59%). Many of them were overweight

(31%) or obese (49%). Based on the questionnaires, it was found that more subjects performed moderate-intensity physical activities (59%) but none engaged in high-intensity exercise. All of the subjects were treated with

**Table 3:** The Number of Subjects with Low, Normal, or High Levels of Adiponectin, Fasting Insulin, and HOMA-IR in the Atorvastatin and Simvastatin Groups

Variables	Categories	Atorvastatin (n=20)		Simvastatin (n=19)	
		Baseline	Post-treatment	Baseline	Post-treatment
Adiponectin	Low (n)	15	13	11	12
	Normal (n)	3	6	7	5
	High (n)	2	1	1	2
P value a		0.564		0.100	
P value b		0.420			
FI	Low (n)	13	13	14	10
	Normal (n)	5	3	1	5
	High (n)	2	4	4	4
P value a		0.564		0.102	
P value b		0.742			
HOMA-IR	Normal (n)	17	15	15	13
	Moderate (n)	1	3	1	2
	High (n)	2	2	3	4
P value a		0.157		0.180	
P value b		0.447			

Adiponectin level: Low = <3µg/mL, Normal = 3-30µg/mL, High = >30µg/mL;  
 Fasting insulin (FI) level: Low = <3µU/mL, Normal = 3-8µU/mL, High = >8µU/mL

<sup>6</sup> OMA-IR: Normal = 0.5-1.4 Moderate = 1.4-2.9, High = >2.9

<sup>a</sup> p-value between baseline and post-treatment; <sup>b</sup> p-value between atorvastatin and simvastatin group

antihypertensive agents, which were mostly prescribed in dual combination. Based on statistical analysis, the demography of both groups <sup>34</sup> is not significantly different in all aspects.

Table 2 presents the mean levels of adiponectin, fasting insulin, and blood glucose in patients before and after being treated with atorvastatin or simvastatin. Although it was not statistically significant, adiponectin level was reduced by 30% in the atorvastatin group, but the fasting insulin and HOMA-IR <sup>30</sup> index were unchanged.

Similar to that in the atorvastatin group, the mean levels of adiponectin and FBG in the simvastatin group were not significantly changed after treatment. Nonetheless, the simvastatin treatment was found to significantly increase the level of fasting insulin (p-value = 0.033). Although statistically not significant, the HOMA-IR value of simvastatin-treated patients increased by 44% post-treatment, which may have a significant clinical effect in terms of insulin resistance.

Table 3 shows the number of patients with low, normal, or high adiponectin <sup>50</sup> levels. The normal plasma adiponectin level ranges from 3 to 30 µg/mL (22) and the normal fasting insulin levels were from 3 to 8 µU/mL. Fifteen out of 20 subjects (75%) in the atorvastatin group had initial

low circulating adiponectin levels (<3 µg/mL), while only 3 subjects had normal and 2 had elevated circulating adiponectin. It is found that the 2 subjects who had distinctively high baseline adiponectin levels also had extremely high circulating insulin. Two-month atorvastatin treatment (20 mg/day) on these subjects led to a decrease in adiponectin levels by 29-60%, hence, resulting in normal adiponectin levels post-treatment.

Meanwhile, in the simvastatin group, 11 patients (58%) experienced low circulating adiponectin levels and 14 patients (73%) had low fasting insulin levels prior to treatment. Three subjects had normal adiponectin levels but the fasting insulin levels were considered elevated. After two months, 1 subject whose initial adiponectin levels were normal, experienced a significant increase in adiponectin levels following simvastatin treatment (20 mg/day). <sup>37</sup>

Based on Spearman's rho correlation test, there was a significant correlation between adiponectin and fasting insulin levels in both groups, before or after treatments (Table 4). Although there was no correlation found between the FBG level and adiponectin, the HOMA-IR value was found to

**Table 4:** Correlation Between Adiponectin Levels and Other Variables Before and After Statin Treatment

Variables	Atorvastatin				Simvastatin			
	Baseline r	p	Post-treatment r	p	Baseline r	p	Post-treatment r	p
FBG	0.035	0.884	-0.053	0.824	0.115	0.640	-0.034	0.889
FI	0.507	0.023*	0.810	0.001**	0.829	0.001**	0.869	0.001**
HOMA-IR	0.508	0.022*	0.775	0.001**	0.831	0.001**	0.869	0.001**
Sex	-0.209	0.376	-0.139	0.558	0.107	0.663	-0.204	0.401
Age	-0.310	0.183	-0.309	0.185	0.201	0.409	0.179	0.463
BMI	0.100	0.674	0.041	0.862	0.265	0.273	0.285	0.238
PA	0.124	0.603	0.151	0.526	-0.136	0.578	-0.107	0.663

FBG: Fasting Blood Glucose; FI: Fasting Insulin; HOMA-IR: Homeostatic Model Assessment-Insulin Resistance; BMI: Body Mass Index; PA Physical Activities; p-values based on Spearman's rho correlation test

significantly correlate with adiponectin levels in both groups.

## Discussion

Based on the guideline on the management of blood cholesterol, statins are the first drug of choice in the primary and secondary prevention of atherosclerotic cardiovascular disease (23). The use of statins is recommended for groups of people with very high-risk future atherosclerotic cardiovascular disease (ASCVD) events and also for people with primary severe hypercholesterolemia (23). Statins have been known to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) by 15-37% (24). However, statins are reported to inhibit glucose metabolism by decreasing circulating adiponectin levels leading to reduced insulin sensitivity (15).

In this study, the subjects were recruited from dyslipidemic non-diabetic patients. The baseline adiponectin levels of the subjects were predominantly low (< 3 µg/mL), which is more likely due to the hypercholesterolemic condition of the subjects involved. Dyslipidemia is associated with low adiponectin levels even in non-diabetic patients (25). Nevertheless, it was found that 3 out of the total 39 dyslipidemic subjects had markedly high baseline adiponectin levels (>50 µg/L). In this present study, no significant correlation was found between the intensity of physical activity and BMI with adiponectin levels in non-diabetic patients. Unlikely, physical activities and BMI were found to correlate with glycemic controls in DM type 2 patients (26).

Another factor that may influence the elevation of adiponectin levels is the use of antihypertensive agents. Several antihypertensive agents have been reported to increase the level of adiponectin including ramipril and valsartan<sup>27</sup>. Apparently, a marked elevation of adiponectin level is not always beneficial, indeed, it has been associated with an increased risk of atrial fibrillation, especially in the elderly (28).

Intriguingly, different types of statin treatments may differently affect circulating adiponectin levels and the risk of glycemic disturbance. Following 2 months of treatments, atorvastatin use had led to a decrease in adiponectin levels by 32%, but it did not reach statistical significance. A similar finding was obtained by Koh and co-worker's study (2010), which also shows that 20 mg/day of atorvastatin led to an insignificant reduction of the adiponectin level in hypercholesteremic patients compared to the baseline (29). In contrast to atorvastatin, simvastatin treatment in this study has led to a rise in adiponectin level by 44%, a significant increase in the fasting insulin level (p<0.05), and a greater HOMA-IR index. This may indicate simvastatin treatment may lead to a progression of insulin resistance after two months, but not with atorvastatin treatment.

A meta-analysis study by Chrusciel et al. (2016) has confirmed that statin therapies, in general, can instigate a significant increase in adiponectin levels, but the authors suggest that the development of hyperglycemia in hypercholesteremic patients may not be related to statins' modulation on circulating adiponectin (30). Again, in this study, we observed a very significant correlation (p<0.01) between the fluctuation of the adiponectin levels and the

fasting insulin levels in both treatment groups. In the atorvastatin group, the adiponectin level was slightly reduced but the FBG, fasting insulin level, and the HOMA-IR index were not significantly modified after treatment. In contrast, simvastatin therapy caused a significant increase in fasting insulin levels simultaneously with an increase in adiponectin levels. It is postulated that different types of statins may elicit different effects on insulin sensitivity, which may relate to their effects on adiponectin levels. Further study with a greater sample size is warranted to be able to confirm this.

Simvastatin, but not atorvastatin, significantly increase the fasting insulin level, and HOMA-IR to a lesser extent, in non-diabetic dyslipidemic patients. The increased level of fasting insulin is significantly correlated with the increase in adiponectin level, suggesting that the two-month simvastatin use may stimulate insulin resistance in this population without reducing the plasma level of adiponectin.

## References

1. Klop B, Elte JWF, and Cabezas MC. Dyslipidemia in obesity: Mechanisms and potential targets. *Nutrients* 2013; 5(4): 1218-1240.
2. Chowdary RP, Praveen D, and Aanandhi VM. A prospective study on the incidence of dyslipidemia in diabetes mellitus. *Research Journal of Pharmacy and Technology* 2017; 10(2): 431-433.
3. Arsyad A, Idris I, Rasyid AA, Usman RA, Faradillah KR, Latif WOU, et al. Long-term ketogenic diet induces metabolic acidosis, anemia, and oxidative stress in healthy wistar rats. *Journal of Nutrition and Metabolism* 2020; 2020: 3642035.
4. Zodda D, Giammona R, and Schifilliti S. Treatment strategy for dyslipidemia in cardiovascular disease prevention: Focus on old and new drugs. *Pharmacy (Basel, Switzerland)* 2018; 6(1): 10.
5. Stancu C and Sima A. Statins: Mechanism of action and effects. *Journal of Cellular and Molecular Medicine* 2001; 5(4): 378-387.
6. Gaikwad PS, Gadhave DU, Pimpodkar NV, and Mandhare TA. Pleiotropic effects of statins. *Asian Journal of Research in Pharmaceutical Science* 2015; 5(1): 55-58.
7. Ashna A, Jeena S, Vidhya P, Venkateswaramurthy N, and Sambathkumar R. Statins: Pleiotropic effect. *Research Journal of Pharmacy and Technology* 2016; 9(7): 977-981.
8. Betteridge DJ and Carmena R. The diabetogenic action of statins—mechanisms and clinical implications. *Nature Reviews Endocrinology* 2016; 12(2): 99-103.
9. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, and Trompet S. The controversies of statin therapy: Weighing the evidence. *Journal of the American College of Cardiology* 2012; 60(10): 875-881.
10. Sari DRAP, Ahmad FF, Djabir YY, and Yulianty R. Breadfruit leaves extract (*Artocarpus altilis*) effect on pancreatic damage in diabetic type ii animal model induced by alloxan–nicotinamide. *Medicina Clínica Práctica* 2020; 3: 100099.
11. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. *Diabetes* 2003; 52(2): 239-243.
12. Ding P, Hsu P, and Lu T. Statin therapy on insulin resistance and plasma level of adiponectin in non-diabetic, hypercholesterolemic patients. *Acta Cardiology* 2009; 25(183): 9.
13. Tao C, Sifuentes A, and Holland WL. Regulation of glucose and lipid homeostasis by adiponectin: Effects on hepatocytes, pancreatic  $\beta$  cells and adipocytes. *Best Practice & Research Clinical Endocrinology & Metabolism* 2014; 28(1): 43-58.
14. Jian L, Su Y, and Deng H. Adiponectin-induced inhibition of intrinsic and extrinsic apoptotic pathways protects pancreatic  $\beta$ -cells against apoptosis. *Hormone and Metabolic Research* 2013; 45(08): 561-566.
15. Chan DC, Pang J, and Watts GF. Pathogenesis and management of the diabetogenic effect of statins: A role for adiponectin and coenzyme q 10? *Current Atherosclerosis Reports* 2015; 17(1): 472-478.
16. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. *Diabetes Care* 2008; 31(4): 776-782.
17. Qu H-y, Xiao Y-w, Jiang G-h, Wang Z-y, Zhang Y, and Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. *Pharmaceutical Research* 2009; 26(4): 958-964.
18. Devaraj S, Siegel D, and Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. *The American Journal of Cardiology* 2007; 100(9): 1397-1399.
19. Sonmez A, Dogru T, Tasci I, Yilmaz MI, Pinar M, Naharci I, et al. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. *Clinical Endocrinology* 2006; 64(5): 567-572.
20. IPAQ, Guidelines for data processing analysis of the international physical activity questionnaire (ipaq) - short and long forms, 2005.

21. Salgado ALFdA, Carvalho Ld, Oliveira AC, Santos VNd, Vieira JG, and Parise ER. Insulin resistance index (homa-ir) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. *Arquivos de Gastroenterologia* 2010; 47: 165-169.
22. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, and Libby P. Adiponectin: A key adipocytokine in metabolic syndrome. *Clinical Science* 2006; 110(3): 267-278.
23. Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R, et al. Guideline on the management of blood cholesterol: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. *Journal of the American College of Cardiology* 2018; 73(24): e285-350.
24. Ahn CH and Choi SH. New drugs for treating dyslipidemia: Beyond statins. *Diabetes & Metabolism Journal* 2015; 39(2): 87-94.
25. Marso SP, Mehta SK, Frutkin A, House JA, McCrary JR, and Kulkarni KR. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. *Diabetes Care* 2008; 31(5): 989-994.
26. Pandian R and Ramalingam M. Consequences of physical activity on the markers of glycemic status among type 2 diabetic subjects. *Research Journal of Pharmacy and Technology* 2012; 5: 1413-1416.
27. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyiletten T, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. *Nephrology* 2007; 12(2): 147-153.
28. Macheret F, Bartz TM, Djousse L, Ix JH, Mukamal KJ, Zieman SJ, et al. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. *Heart (British Cardiac Society)* 2015; 101(17): 1368-1374.
29. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, and Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. *Journal of the American College of Cardiology* 2010; 55(12): 1209-1216.
30. Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban M-C, Ursoniu S, Mikhailidis DP, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. *Atherosclerosis* 2016; 253: 194-208.

# and\_Insulin\_Resistance\_In\_Non-Diabetic\_Dyslipidemic\_Patients.pdf

## ORIGINALITY REPORT

22%

SIMILARITY INDEX

15%

INTERNET SOURCES

16%

PUBLICATIONS

5%

STUDENT PAPERS

## PRIMARY SOURCES

- 1 Nurfadilah Nurfadilah, Yulia Yusrini Djabir, Siti Aminah, Yulita Chrismensi Patimang, Arif Santoso, Risfah Yulianty. "Black Seed Oil Protects Against Levofloxacin Hepatotoxicity: Analyses of the Biochemical and Histopathological Effects", Iranian Journal of Toxicology, 2022  
Publication 1%
- 2 Po-Shiuan Hsieh. "Chapter 10 Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance", IntechOpen, 2011  
Publication 1%
- 3 Anitsah Fiqardina, Yulia Yusrini Djabir, Arif Santoso, Syafira Nurul Salsabil, Ismail Ismail. "The Nephroprotective Effect of Clove Oil (Oleum Caryophylli) Against Levofloxacin Toxicity in Rats", Iranian Journal of Toxicology, 2022  
Publication 1%

4

Jinxing Liu, Chengping Hu, Yan Liu, Yong Zhu, Hongya Han, Yujie Zhou, Yingxin Zhao.

"Association Between Surrogate Index of Insulin Resistance and Coronary Collateral Circulation in Patients with Coronary Chronic Total Occlusion Lesions", Research Square Platform LLC, 2021

Publication

1 %

5

[ejechocard.prod-oup.highwire.org](http://ejechocard.prod-oup.highwire.org)

Internet Source

1 %

6

Majid Meshkini, Fariba Alaei-Shahmiri, Cyril Mamotte, Jaya Earnest. "Ethnic Variation in Lipid Profile and Its Associations with Body Composition and Diet: Differences Between Iranians, Indians and Caucasians Living in Australia", Journal of Immigrant and Minority Health, 2016

Publication

1 %

7

[publications.aston.ac.uk](http://publications.aston.ac.uk)

Internet Source

1 %

8

Dick C. Chan, Jing Pang, Gerald F. Watts. "Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?", Current Atherosclerosis Reports, 2014

Publication

1 %

9	Tongluk Teerasarntipan, Roongruedee Chaiteerakij, Piyapan Prueksapanich, Duangporn Werawatganon. "Changes in Inflammatory Cytokines, Antioxidants and Liver Stiffness after Chelation Therapy in Individuals with Chronic Lead Poisoning", Research Square Platform LLC, 2019 Publication	1 %
10	<a href="http://journal2.uad.ac.id">journal2.uad.ac.id</a> Internet Source	1 %
11	<a href="http://www.recentmedicalfindings.com">www.recentmedicalfindings.com</a> Internet Source	1 %
12	<a href="http://www.thieme-connect.de">www.thieme-connect.de</a> Internet Source	1 %
13	<a href="http://makhillpublications.co">makhillpublications.co</a> Internet Source	<1 %
14	<a href="http://www.ijpsonline.com">www.ijpsonline.com</a> Internet Source	<1 %
15	<a href="http://www.novctrd.com">www.novctrd.com</a> Internet Source	<1 %
16	Alexios S. Antonopoulos, Regent Lee, Marios Margaritis, Charalambos Antoniades. "Adiponectin as a Regulator of Vascular Redox State: Therapeutic Implications", Recent Patents on Cardiovascular Drug Discovery, 2011	<1 %

---

17	<a href="#">Submitted to Curtin University of Technology</a> Student Paper	<1 %
18	<a href="#">bmcpychiatry.biomedcentral.com</a> Internet Source	<1 %
19	<a href="#">cvi.asm.org</a> Internet Source	<1 %
20	<a href="#">dmsjournal.biomedcentral.com</a> Internet Source	<1 %
21	<a href="#">www.cambridge.org</a> Internet Source	<1 %
22	Bailu Geng, Xueli Ding, Xiaoyu Li, Hua Liu, Wenjun Zhao, Haihong Gong, Zibin Tian, Jing Guo. "Peripheral blood T-lymphocyte subsets are potential biomarkers of disease severity and clinical outcomes in patients with ulcerative colitis: a retrospective study", BMC Gastroenterology, 2023 Publication	<1 %
23	<a href="#">app.trdizin.gov.tr</a> Internet Source	<1 %
24	<a href="#">diabetesjournals.org</a> Internet Source	<1 %
25	<a href="#">jcimcr.org</a> Internet Source	<1 %

---

26	<a href="https://journals.plos.org">journals.plos.org</a> Internet Source	<1 %
27	<a href="https://ourarchive.otago.ac.nz">ourarchive.otago.ac.nz</a> Internet Source	<1 %
28	<a href="https://sitecore93prod.heart.org">sitecore93prod.heart.org</a> Internet Source	<1 %
29	"Bariatric Endocrinology", Springer Science and Business Media LLC, 2019 Publication	<1 %
30	Hamideh A. Lolaty, Sharbanoo Ghahari, Abdolhakim Tirgari, Jabbar Heydari Fard. "The Effect of Life Skills Training on Emotional Intelligence of the Medical Sciences Students in Iran", Indian Journal of Psychological Medicine, 2020 Publication	<1 %
31	<a href="https://annalsofglobalhealth.org">annalsofglobalhealth.org</a> Internet Source	<1 %
32	<a href="https://e-cmh.org">e-cmh.org</a> Internet Source	<1 %
33	<a href="https://edoc.unibas.ch">edoc.unibas.ch</a> Internet Source	<1 %
34	<a href="https://eprints.mums.ac.ir">eprints.mums.ac.ir</a> Internet Source	<1 %
35	<a href="https://nephropathol.com">nephropathol.com</a> Internet Source	<1 %

<1 %

36

[pure-oai.bham.ac.uk](http://pure-oai.bham.ac.uk)

Internet Source

<1 %

37

[www.ejmcm.com](http://www.ejmcm.com)

Internet Source

<1 %

38

[www.siditalia.it](http://www.siditalia.it)

Internet Source

<1 %

39

CL Harrison. "Understanding health behaviours in a cohort of pregnant women at risk of gestational diabetes mellitus: an observational study : Health behaviours in high GDM risk pregnancies", BJOG An International Journal of Obstetrics & Gynaecology, 05/2012

Publication

<1 %

40

Devaraj, S.. "Simvastatin (40 mg/day), Adiponectin Levels, and Insulin Sensitivity in Subjects With the Metabolic Syndrome", The American Journal of Cardiology, 20071101

Publication

<1 %

41

E. Moutzouri. "Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance : Lipid-lowering treatment and glucose", International Journal of Clinical Practice, 11/2011

<1 %

42 Michael S. Kostapanos, George L. Liamis, Haralampos J. Milionis, Moses S. Elisaf. "Do Statins Beneficially or Adversely Affect Glucose Homeostasis?", *Current Vascular Pharmacology*, 2010

Publication

---

43 Nurlindah Hamrun, Muhammad Ruslin, Erni Marlina, Sri Oktawati, Takashi Saito, Andi Siti Hajrah Yusuf, Keng-Liang Ou. "Vitamin D Receptor Gene Polymorphism as a Risk Factor for Chronic Periodontitis", *Research Square Platform LLC*, 2021

Publication

---

44 [effectivehealthcare.ahrq.gov](http://effectivehealthcare.ahrq.gov)  
Internet Source

45 [indianheartjournal.com](http://indianheartjournal.com)  
Internet Source

46 [jscholarship.library.jhu.edu](http://jscholarship.library.jhu.edu)  
Internet Source

47 [nrcrm.gov.ua](http://nrcrm.gov.ua)  
Internet Source

48 [pdfs.semanticscholar.org](http://pdfs.semanticscholar.org)  
Internet Source

49 [repositories.lib.utexas.edu](http://repositories.lib.utexas.edu)  
Internet Source

---

50	res.mdpi.com Internet Source	<1 %
51	www.actapharmsci.com Internet Source	<1 %
52	www.mercycareaz.org Internet Source	<1 %
53	"Oral Presentations", Obesity Reviews, 9/2006 Publication	<1 %
54	Adams, Stephen P, Michael Tsang, James M Wright, and Stephen P Adams. "Lipid lowering efficacy of atorvastatin", Cochrane Database of Systematic Reviews Reviews, 2012. Publication	<1 %
55	Bello Chavolla Omar Yaxmehen. "Desarrollo de un modelo predictivo para la incidencia de demencia en adultos mayores con diabetes mellitus tipo 2", TESIUNAM, 2019 Publication	<1 %
56	J P Beilby. "Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity", International Journal of Obesity, 05/2008 Publication	<1 %
57	Minchao Li, Nan Li, Haidi Wu, Qinglin Lou, Jiangyi Yu, Liubao Gu, Liji Huang. "Serum uric	<1 %

acid predicts progression of islet beta cell function decline in female patients with type 2 diabetes mellitus", Research Square Platform LLC, 2023

Publication

---

58

liang, Yaojie, Aihua Tan, Danyan Liang, Xiaobo Yang, Ming Liao, Yong Gao, Yonghua Jiang, Ziting Yao, Xinggu Lin, Zheng Lu, Chunlei Wu, Shijun Zhang, Yanlin Hu, Xue Qin, Zengnan Mo, and Haiying Zhang. "Low osteocalcin level is a risk factor for impaired glucose metabolism in Chinese male population", Journal of Diabetes Investigation, 2015.

Publication

---

59

"Abstracts from the 30th Annual Meeting of the Society of General Internal Medicine", Journal of General Internal Medicine, 2007

Publication

---

60

"Endocrine Disorders in Kidney Disease", Springer Nature, 2019

Publication

---

61

Barbara Cybulska, Longina Kłosiewicz-Latoszek. "How do we know that statins are diabetogenic and why? Is it an important issue in the clinical practice?", Kardiologia Polska, 2014

Publication

---

<1 %

<1 %

<1 %

<1 %

62

Chung-Ze Wu, Chung-Yu Lin, Fang-Yu Chen, Chun-Heng Kuo, Jin-Shuen Chen, Pietro Pitrone, Li-Ying Huang. "The Comparison of Accuracy between Traditional Logistic Regression and Gradient Boosting Classifier Model of Artificial Intelligence in Predicting Diabetes Kidney Disease in Chinese – A 4-year Longitudinal Study", Research Square Platform LLC, 2023

Publication

<1 %

63

Kater, A.L.d.A.. "Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe", Metabolism, 201006

Publication

<1 %

64

Ming-Ling Chang, Chia-Jung Kuo, Li-Heng Pao, Chen-Ming Hsu, Cheng-Tang Chiu. "The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance", Virulence, 2017

Publication

<1 %

Exclude quotes  On

Exclude matches  < 5 words

Exclude bibliography  On